The BCG replacement vaccine VPM1002: from drawing board to clinical trial-Reference-Cited by-同舟云学术

The BCG replacement vaccine VPM1002: from drawing board to clinical trial

Published:2014-04-07 Issue:5 Volume:13 Page:619-630
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Kaufmann Stefan HE¹,Cotton Mark F²,Eisele Bernd³,Gengenbacher Martin¹,Grode Leander³,Hesseling Anneke C²,Walzl Gerhard²

Affiliation:

1. Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany

2. Department of Paediatrics and Child Health, Desmond Tutu Tuberculosis Centre, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa

3. Vakzine Projekt Management GmbH, Hannover, Germany

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1586/14760584.2014.905746

Reference120 articles.

1. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies

2. Immunological biomarkers of tuberculosis

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Live Attenuated Vaccines against Tuberculosis: Targeting the Disruption of Genes Encoding the Secretory Proteins of Mycobacteria;Vaccines;2024-05-12

2. Tuberculosis vaccine developments and efficient delivery systems: A comprehensive appraisal;Heliyon;2024-02

3. Tuberculosis vaccine - A timely analysis of the drawbacks for the development of novel vaccines;Indian Journal of Tuberculosis;2023-12

4. The Promising Potential of Reverse Vaccinology-Based Next-Generation Vaccine Development over Conventional Vaccines against Antibiotic-Resistant Bacteria;Vaccines;2023-07-20

5. Vaccines against Tuberculosis: Where Are We Now?;Vaccines;2023-05-22